The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Balversa Launched in Japan as 1st Genetically Targeted Drug for Bladder Cancer: J&J
Janssen Pharmaceutical (J&J) said on July 16 that Balversa (erdafitinib) is now available in Japan for the treatment of unresectable urothelial carcinoma harboring FGFR3 genetic mutations or gene fusions that has progressed following cancer chemotherapy. Balversa, an FGFR inhibitor, is…
To read the full story
Related Article
- Janssen’s Balversa Gets Green Light for NHI Listing
July 10, 2025
BUSINESS
- Kyorin Licenses Lasvic to UAE’s Lunatus for Middle East Markets
January 6, 2026
- Sanofi to Transfer Jevtana Sales to Taiho from April
January 6, 2026
- Meiji Restarts Domestic 6-APA Production after 31-Year Hiatus
January 5, 2026
- Meiji Files NDA for Nacubactam in Japan
January 5, 2026
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…